Core Viewpoint - A class action has been filed against Zenas BioPharma, Inc. for allegedly misleading investors during its IPO, particularly regarding the company's financial sustainability and operational funding timeline [1][2]. Group 1: Allegations and Financial Misrepresentation - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations, claiming it could sustain operations for twenty-four months instead of the actual twelve months as disclosed in its Form 10-Q filed on November 12, 2024 [2]. - Following the revelation of these material adverse facts, Zenas BioPharma's stock price has significantly declined, closing at $8.72 on April 15, 2025, which is 48.7% lower than its IPO price [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by June 16, 2025, while those who choose not to participate can remain as absent class members [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to opt for passive involvement [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [4]. - The firm has a history of advocating for shareholder rights and aims to hold company executives accountable for their actions [4].
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How to Lead the Class Action Against Zenas BioPharma, Inc.